Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group

Major chemotherapeutic alternatives for AML have been implemented and compared in three multicenter studies, including a total of 877 adult patients of all ages. The results strongly suggest that myelosuppressive postinduction treatment is a prerequisite for the achievement of long-term remissions....

Full description

Saved in:
Bibliographic Details
Published inHaematology and blood transfusion Vol. 30; p. 57
Main Authors Büchner, T, Hiddemann, W, Urbanitz, D, Kreutzmann, H, Maschmeyer, G, Wendt, F, Kuse, R, Mohr, A, Gassmann, W, Löffler, H
Format Journal Article
LanguageEnglish
Published Germany 1987
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Clinical Trials as Topic
Cytarabine - administration & dosage
Daunorubicin - administration & dosage
Germany, West
Humans
Leukemia, Myeloid, Acute - drug therapy
Mitoxantrone - administration & dosage
Random Allocation
Remission Induction
Thioguanine - administration & dosage
Germany, West
Online AccessGet more information

Cover

More Information
Summary:Major chemotherapeutic alternatives for AML have been implemented and compared in three multicenter studies, including a total of 877 adult patients of all ages. The results strongly suggest that myelosuppressive postinduction treatment is a prerequisite for the achievement of long-term remissions. In addition, it was possible to establish an important antileukemic effect of monthly maintenance chemotherapy. Initial results from an intensive two-course preremission therapy concept revealed good practicability and acceptable toxicity, as well as promising response and remission durations by this new approach.
ISSN:0171-7111
DOI:10.1007/978-3-642-71213-5_10